Clinical Trials on Hereditary Ovarian Carcinoma

Total 28181 results

Gynecologic Oncology Group
National Cancer Institute (NCI)

Not yet recruiting

Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199

Fallopian Tube Carcinoma | Ovarian Carcinoma | Hereditary Breast and Ovarian Cancer Syndrome | Primary Peritoneal Carcinoma

United States
Georgetown University

Completed

Enhancing At-risk Latina Women's Use of Genetic Counseling for Hereditary Breast and Ovarian Cancer

Hereditary Breast and Ovarian Cancer

United States
Emory University

Completed

Identification and Referral of Women at Risk for Hereditary Breast/Ovarian Cancer

Hereditary Breast and Ovarian Cancer

United States
UNICANCER
Institut National de la Santé Et de la Recherche Médicale, France; Gustave... and other collaborators

Recruiting

Investigation of Tumour Spectrum of Germline Mutations in Breast and Ovarian Cancer Genes. (TUMOSPEC)

Mutation | Hereditary Breast and Ovarian Cancer

France
University of Kansas Medical Center

Recruiting

Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry (PROGECT)

Breast Cancer | Hereditary Breast and Ovarian Cancer

United States
Abramson Cancer Center at Penn Medicine

Enrolling by invitation

Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition

Ovarian Cancer | Genetic Predisposition to Disease | Breast Cancer Female | Hereditary Diseases | Gene Mutation-Related Cancer | Hereditary Breast and Ovarian Cancer | Hereditary Cancer Syndrome

United States
COL George Peoples, MD, FACS
M.D. Anderson Cancer Center

Completed

Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients (J65)

Breast Cancer | Ovarian Cancer

United States
National Cancer Institute (NCI)

Completed

AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer

Breast Cancer | Ovarian Cancer

United States
M.D. Anderson Cancer Center

Completed

Attitudes About Childbearing And Fertility With Inherited Breast And Ovarian Cancer Syndromes (HBOC)

Breast Cancer | Ovarian Cancer

United States
National Cancer Institute (NCI)

Completed

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Breast Carcinoma | Ovarian Carcinoma | Pancreatic Carcinoma | Prostate Carcinoma | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative... and other conditions

United States
Peking Union Medical College Hospital

Unknown

Inherited Susceptible Genes Among Epithelial Ovarian Cancer

Hereditary Breast and Ovarian Cancer Syndrome | Ovarian Neoplasm Epithelial

China
Centre Jean Perrin
Fondation de l'Avenir et la MASFIP, Paris - France

Terminated

Impact of a Psychoeducational Intervention on Expectations and Coping in Young Women Exposed to a High HBOC Risk

Hereditary Breast and Ovarian Cancer Syndrome

France
Centre Francois Baclesse

Completed

Search Allelic Imbalance of Expression of BRCA Genes in Hereditary Risk of Breast and/or Ovarian Cancer (EXSAL)

Hereditary Breast and Ovarian Cancer Syndrome

France
OHSU Knight Cancer Institute
National Cancer Institute (NCI); Oregon Health and Science University

Recruiting

Identifying and Caring for Individuals With Inherited Cancer Syndrome

Malignant Solid Neoplasm | Lynch Syndrome | Hematopoietic and Lymphoid System Neoplasm | Breast Ductal Carcinoma In Situ | Hereditary Neoplastic Syndrome | BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome

United States
Aspira Women's Health

Terminated

Multifactorial Risk Assessment for Breast & Ovarian Cancer Risk Detection (OVA360)

Hereditary Breast and Ovarian Cancer | Adnexal Mass | Germline BRCA1 Gene Mutation | Germline BRCA2 Gene Mutation

United States
Institut Paoli-Calmettes
UNICANCER - Le Groupe génétique et cancer (GGC)

Recruiting

Genetic Predisposition to Breast and Ovarian Cancer: Prospective Study of BRCAx Gene Mutation (GENEPSO)

Breast Cancers | Ovarian Cancers

France
Institut Claudius Regaud

Unknown

Evaluation of the Adhesion to the GENEPY Network (GENEPY)

Hereditary Breast and Ovarian Cancer | Hereditary Cancer Syndrome | Hereditary Colorectal Endometrial Cancer Syndrome

France
AstraZeneca

Completed

C-PATROL - Non-interventional Study (NIS) to Collect Clinical and Patient Reported Outcome Data in an Olaparib Treated BRCAm+ PSR Ovarian Cancer Population (C-PATROL)

Ovarian Cancer, Hereditary Ovarian Cancer Syndrome

Germany
Washington University School of Medicine
The Foundation for Barnes-Jewish Hospital

Terminated

Implementation of the Families Accelerating Cascade Testing Toolkit (FACTT) for Hereditary Breast and Ovarian Cancer and Lynch Syndrome

Lynch Syndrome | Hereditary Breast and Ovarian Cancer

United States
University of Basel

Recruiting

Cascade Genetic Testing for Hereditary Breast/Ovarian Cancer and Lynch Syndrome in Switzerland (CASCADE)

Lynch Syndrome | Hereditary Breast and Ovarian Cancer

Switzerland
Duke University
Susan G. Komen Breast Cancer Foundation

Completed

Telemedicine vs. Face-to-Face Cancer Genetic Counseling

Lynch Syndrome | Hereditary Breast and Ovarian Cancer Syndrome

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Culturally-Informed Counseling in Latinas at High Risk for Hereditary Breast or Ovarian Cancer

BRCA1 Syndrome | BRCA2 Syndrome | No Evidence of Disease | Hereditary Ovarian Carcinoma | Hereditary Female Breast Carcinoma

United States
Lei Li

Recruiting

Risk-Reducing Surgeries for Hereditary Ovarian Cancer

Colorectal Neoplasms, Hereditary Nonpolyposis | Hysterectomy | Hereditary Breast and Ovarian Cancer Syndrome | Ovariectomy

China
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries

Osteoporosis | Ovarian Carcinoma | Hereditary Breast and Ovarian Cancer Syndrome

United States
Georgetown University
Virginia Commonwealth University; Cornell University

Completed

Testing an Intelligent Tutoring System to Enhance Genetic Risk Assessment

Hereditary Breast and Ovarian Cancer

United States
University of Southern California
Stanford University

Completed

Cancer Genetics Hereditary Cancer Panel Testing (HCP)

Hereditary Breast and Ovarian Cancer

United States
Aivita Biomedical, Inc.

Active, not recruiting

Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas

Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Stage III Ovarian Carcinoma | Stage IV Ovarian Carcinoma

United States
National Human Genome Research Institute (NHGRI)

Completed

Is it Feasible?: Self-Affirmation for Hereditary Breast and Ovarian Cancer Genetic Counseling

Breast Cancer

United States
Fundació Institut de Recerca de l'Hospital de la...

Recruiting

Study of Quality of Life Post Salpingo-oophorectomy in BRCA1/2 & PALB2 Mutation Carriers (BRCA-HRT) (BRCA-HRT)

Hereditary Breast and Ovarian Cancer

Spain
Women's Hospital School Of Medicine Zhejiang University
Sun Yat-sen University; Qilu Hospital of Shandong University; Second Affiliated... and other collaborators

Recruiting

Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer

Epithelial Ovarian Carcinoma Stage III | Epithelial Ovarian Carcinoma Stage IV | Fallopian Tube Carcinoma Stage III | Fallopian Tube Carcinoma Stage IV | Primary Peritoneal Carcinoma Stage III | Primary Peritoneal Carcinoma Stage IV

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Weight Management and Health Behavior Intervention in Lowering Cancer Risk for BRCA Positive and Lynch Syndrome Families

Lynch Syndrome | Hereditary Breast Carcinoma | Hereditary Ovarian Carcinoma

United States
OHSU Knight Cancer Institute

Withdrawn

N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer

Primary Peritoneal Carcinoma | Epithelial Ovarian Carcinoma | Ovarian Carcinoma, Stage 3 or 4

United States
Hospices Civils de Lyon

Completed

Low Grade Serous Ovarian Carcinoma and Uterine Involvement : Should Hysterectomy be the Rule (LOGYST)

Serous Ovarian Carcinoma | Low Grade Serous Ovarian Carcinoma

France
Mayo Clinic
National Cancer Institute (NCI)

Completed

Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Recurrent Ovarian Germ Cell Tumor | Undifferentiated Ovarian Carcinoma | Ovarian Serous...

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer

Recurrent Ovarian Carcinoma | Ovarian Neoplasm | Ovarian Clear Cell Tumor | Adnexal Mass | Ovarian Endometrioid Tumor | Ovarian Serous Tumor | Borderline Ovarian Epithelial Tumor

United States
Northwestern University
National Cancer Institute (NCI); Ipsen Biopharmaceuticals

Completed

Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian Carcinoma | Refractory Fallopian Tube... and other conditions

United States
Barretos Cancer Hospital

Completed

Neoadjuvant Carboplatin in Triple Negative Breast Cancer

BRCA1 Hereditary Breast and Ovarian Cancer Syndrome

Brazil
University of Washington
National Cancer Institute (NCI)

Completed

Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer

Male Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast Cancer | Hereditary Breast/Ovarian Cancer - BRCA1 | Hereditary Breast/Ovarian Cancer...

United States
Roswell Park Cancer Institute

Completed

Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian Cancer

Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Stage IIA Ovarian Cancer | Stage IIB Ovarian Cancer | Stage IIC Ovarian Cancer | Stage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian Cancer | Stage IA Ovarian Cancer | Stage IB Ovarian Cancer | Stage IC... and other conditions

United States
Johns Hopkins University
National Human Genome Research Institute (NHGRI)

Completed

Genetic Risk: Whether, When, and How to Tell Adolescents

Huntington Disease | Hereditary Cancer | Hereditary Breast and Ovarian Cancer | Hereditary Non-polyposis Colon Cancer | Hereditary Non-Polyposis Colorectal Cancer Syndrome

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Fallopian Tube Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube... and other conditions

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Withdrawn

Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy

Recurrent Ovarian Carcinoma | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Stage IV Ovarian Cancer | Stage III Ovarian Cancer

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Undifferentiated Ovarian Carcinoma

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
National Institutes of Health (NIH)

Terminated

Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Malignant Ovarian Endometrioid Tumor | Malignant Ovarian Serous Tumor

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous... and other conditions

United States
Xian-Janssen Pharmaceutical Ltd.

Terminated

A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy

Epithelial Ovarian Cancer

China
National Cancer Institute (NCI)
AstraZeneca; NRG Oncology

Active, not recruiting

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian... and other conditions

United States, Canada, Korea, Republic of, Japan
University of Miami

Withdrawn

LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma

Ovarian Cancer | Recurrent Ovarian Carcinoma | Ovarian Carcinoma | Recurrent Ovarian Cancer
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Ovarian Undifferentiated Carcinoma

United States
Translational Research Center for Medical Innovation...
Okayama University; Japanese Gynecologic Oncology Group (JGOG)

Recruiting

Prospective Cohort Study of Germline Variant Carriers With BRCA1 or BRCA2

Fallopian Tube Carcinoma | Peritoneal Carcinoma | Ovarian Carcinoma | BRCA1 and/or BRCA2 Variant Carriers

Japan

Clinical Trials on Hereditary Ovarian Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations